Levetiracetam Hikma (Levetiracetam)

Levetiracetam works by binding to the synaptic vesicle protein SV2A, which modulates neurotransmitter release. This action stabilizes neuronal firing and reduces hyper‑excitability, helping to prevent the initiation and spread of seizure activity.

The dose of Levetiracetam Hikma is determined by the prescribing clinician based on the patient’s age, weight, renal function, seizure type and severity. No fixed regimen is provided here; the prescriber tailors the dosage to individual therapeutic needs.

Safety data for levetiracetam during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Consultation with a specialist is recommended before initiating therapy.

To order Levetiracetam Hikma, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The team then provides pricing, availability, shipping details (including cold‑chain handling) and assists with import documentation.

Levetiracetam offers a distinct mechanism (SV2A binding) and is generally well tolerated compared with older agents such as carbamazepine or valproate, which have more enzyme‑inducing or hepatotoxic potential. It has fewer drug‑drug interactions but may cause behavioral changes in some patients.

Levetiracetam Hikma should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Maintain the cold‑chain during transport and keep the product in its original packaging until use.

Levetiracetam Hikma is administered as an intravenous infusion. The solution is diluted in an appropriate compatible fluid and infused over a period defined by the prescriber, typically ranging from a few minutes to several hours depending on clinical need.

Serious risks include severe allergic reactions such as anaphylaxis, life‑threatening skin conditions like Stevens‑Johnson syndrome, and emergence of suicidal thoughts or behaviors. Patients should be monitored closely for any signs of these events and medical attention sought immediately if they occur.

Levetiracetam Hikma should be avoided in individuals with known hypersensitivity to levetiracetam or any component of the formulation. Patients with severe renal impairment who cannot be dose‑adjusted, or those with uncontrolled psychiatric conditions, should also be evaluated carefully before use.